EL7.AI
StocksMediumUpdated•Originally published 31 July 2026•Updated 31 July 2026•
2 min read

Baxter and UDR Beat Q2 Estimates as Analyst Outlooks Diverge

Key Facts

1Baxter International reported adjusted EPS of $0.56, significantly beating the estimated $0.36.
2Baxter raised its 2026 sales growth forecast to 3%-4% and increased its adjusted EPS guidance.
3Real estate trust UDR reported FFOA per share of $0.64, surpassing analyst estimates.
4Goldman Sachs lowered UDR's price target to $38 despite strong results, citing market headwinds.

In a move reflecting resilience across the healthcare and real estate sectors, Baxter International and UDR reported strong second-quarter 2026 financial results that surpassed analyst estimates. Baxter reported adjusted earnings per share (EPS) of $0.56, significantly beating the estimated $0.36, driven by robust demand in its drug compounding and advanced surgery segments. Consequently, the company raised its 2026 sales growth forecast to a range of 3%-4% and increased its adjusted EPS guidance.

Separately, the real estate investment trust UDR reported adjusted funds from operations (FFOA) of $0.64 per share, exceeding market expectations. However, Goldman Sachs adopted a cautious stance by lowering UDR's price target to $38, citing market headwinds such as slow rent recovery and oversupply. Per market data, Goldman Sachs (GS) shares closed at $1024.86 on July 30, 2026, while peers JPM and MS stood at $350.85 and $210.13 respectively as of the same date.

Investors are now watching for the sustainability of this growth amid current market volatility, with GS priced at $1024.86 (close July 30, 2026) after a daily range between $998.51 and $1029.79. Looking ahead, traders are assessing the impact of recent monetary policy shifts, including the Fed Interest Rate Decision on July 29, to gauge the future trajectory for the real estate and healthcare sectors.